Technology vs. medication monitoring for buprenorphine in pregnancy
Part of Brain & nervous system, Mental health clinical trials.
This study compares two approaches to help pregnant people stay on buprenorphine (a medication for opioid use disorder): one uses technology to support therapy, and the other uses standard medication monitoring. It aims to see which method works better for keeping you in treatment during pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently pregnant, between 13 weeks and 32 weeks 6 days (about 3 to 8 months).
- You have a current or past opioid use disorder within the last 3 years.
- You have a prescription for buprenorphine (Suboxone, Subutex, or Zubsolv) to treat opioid use disorder.
- You live in the United States and are 18 to 45 years old.
- You are not carrying more than one baby, and your pregnancy is not high-risk (no severe nausea, high blood pressure, placenta previa, or bleeding after the first trimester).
- You do not have active suicidal thoughts, psychotic symptoms, or other conditions that would make it hard to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at ways to predict and reduce harmful outcomes for pregnant people with opioid use disorder (OUD) and their babies. It focuses on people who are already receiving ongoing medication treatment during pregnancy and will follow them around delivery at a specific hospital.
This study looks at pregnancy and baby outcomes for people who are pregnant and taking buprenorphine for opioid use disorder. It may help doctors understand what to expect long-term for both parent and child when opioid treatment continues during pregnancy.
This study compares two medications, methadone and buprenorphine, to see which helps people stay in treatment for opioid use disorder. You may be eligible if you are starting a new treatment episode.
This study looks at how the placenta and baby's development may be affected when a mother takes buprenorphine or methadone for opioid use disorder during pregnancy. It aims to find better ways to monitor health and improve outcomes for both mothers and babies.
This study tests a postpartum intervention for mothers diagnosed with opioid use disorder (or receiving opioid addiction treatment) to help during the period after having a baby. You may be eligible if you have a young child and can complete the study tasks, including possible questionnaires and an MRI if needed.
This study tests if adding a medication called guanfacine and mindfulness meditation to standard buprenorphine treatment helps people with opioid use disorder. It looks at whether this combination can improve treatment outcomes and reduce opioid use.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.